The Complexities of Diagnosis with Co-Existing Gaucher Disease and Hemato-Oncology—A Case Report and Review of the Literature
暂无分享,去创建一个
[1] M. Cappellini,et al. Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry , 2022, American journal of hematology.
[2] S. Revel-Vilk,et al. Enzyme replacement therapy leading to improvement in myeloma indices in a patient with concomitant Gaucher disease , 2022, Internal medicine journal.
[3] M. Yuseff,et al. Alterations in Lysosome Homeostasis in Lipid-Related Disorders: Impact on Metabolic Tissues and Immune Cells , 2021, Frontiers in Cell and Developmental Biology.
[4] S. Packman,et al. Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results , 2021, American journal of hematology.
[5] J. Szer,et al. Hematological manifestations and complications of Gaucher disease , 2021, Expert review of hematology.
[6] J. Charrow,et al. Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment. , 2021, Molecular genetics and metabolism.
[7] P. Mistry,et al. Gaucher disease: Basic and translational science needs for more complete therapy and management. , 2020, Molecular genetics and metabolism.
[8] S. Revel-Vilk,et al. A patient with Gaucher disease and plasma cell dyscrasia: bidirectional impact. , 2020, Hematology. American Society of Hematology. Education Program.
[9] P. Steele,et al. Outcomes of screening for gammopathies in children and adults with Gaucher disease type 1 in a cohort from Brazil and the United States , 2020, American journal of medical genetics. Part C, Seminars in medical genetics.
[10] H. Avet-Loiseau,et al. Risk and Response-Adapted Treatment in Multiple Myeloma , 2020, Cancers.
[11] J. Szer,et al. Patient reported outcome measures in a large cohort of patients with type 1 Gaucher disease , 2020, Orphanet Journal of Rare Diseases.
[12] Shaji K. Kumar,et al. Multiple myeloma current treatment algorithms , 2020, Blood Cancer Journal.
[13] A. Chadburn,et al. Synchronous multiple myeloma and Gaucher disease. , 2020, Hematology/oncology and stem cell therapy.
[14] M. Dhodapkar,et al. Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy. , 2020, Molecular genetics and metabolism.
[15] N. Therville,et al. Are Glucosylceramide-Related Sphingolipids Involved in the Increased Risk for Cancer in Gaucher Disease Patients? Review and Hypotheses , 2020, Cancers.
[16] L. Poll,et al. Gaucher Disease in Bone: From Pathophysiology to Practice , 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[17] K. Fiedoruk,et al. Defective Sphingolipids Metabolism and Tumor Associated Macrophages as the Possible Links Between Gaucher Disease and Blood Cancer Development , 2019, International journal of molecular sciences.
[18] M. Pfreundschuh,et al. Saposin C is a frequent target of paraproteins in Gaucher disease‐associated MGUS/multiple myeloma , 2018, British journal of haematology.
[19] M. Foster,et al. Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial , 2018, American journal of hematology.
[20] T. Betsuyaku,et al. Tumor associated macrophages support the growth of FGF9-induced lung adenocarcinoma by multiple mechanisms. , 2018, Lung cancer.
[21] A. Canbay,et al. Hepatocellular carcinoma in Gaucher disease: an international case series , 2018, Journal of Inherited Metabolic Disease.
[22] O. Goker-Alpan,et al. Gaucheromas: When macrophages promote tumor formation and dissemination. , 2018, Blood cells, molecules & diseases.
[23] B. Győrffy,et al. Tumor‐associated macrophages (TAMs) depend on ZEB1 for their cancer‐promoting roles , 2017, The EMBO journal.
[24] J. Szer,et al. Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians. , 2017, Molecular genetics and metabolism.
[25] D. Hughes,et al. Lysosomal Storage Disorders and Malignancy , 2017, Diseases.
[26] J. Stirnemann,et al. A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments , 2017, International journal of molecular sciences.
[27] M. Dhodapkar,et al. Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma. , 2016, The New England journal of medicine.
[28] G. Castaman,et al. Hematological manifestations and complications of Gaucher disease , 2016, Expert review of hematology.
[29] J. Marugan,et al. Lysosomal storage and impaired autophagy lead to inflammasome activation in Gaucher macrophages , 2015, Aging cell.
[30] S. Karlsson,et al. Inhibition of UDP‐glucosylceramide synthase in mice prevents Gaucher disease‐associated B‐cell malignancy , 2015, The Journal of pathology.
[31] S. Işıksoy,et al. Gaucher Cells or Pseudo-Gaucher Cells: That’s the Question , 2014, Turkish journal of haematology : official journal of Turkish Society of Haematology.
[32] T. Park,et al. Chronic myeloid leukemia with marked splenomegaly and pseudo-Gaucher cells , 2013, Blood research.
[33] A. Mehta,et al. Diagnosing Gaucher disease: an on-going need for increased awareness amongst haematologists. , 2013, Blood cells, molecules & diseases.
[34] A. Sohani,et al. Pseudo‐Gaucher cells in disseminated mycobacterial infection , 2013, American journal of hematology.
[35] D. Roggenbuck,et al. Acute inflammatory neuropathy with monoclonal anti-GM2 IgM antibodies, IgM-κ paraprotein and additional autoimmune processes in association with a diffuse large B-cell non-Hodgkin's lymphoma , 2013, BMJ Case Reports.
[36] S. Morad,et al. Ceramide-orchestrated signalling in cancer cells , 2012, Nature Reviews Cancer.
[37] D. Schatz,et al. Dendritic cell-mediated activation-induced cytidine deaminase (AID)-dependent induction of genomic instability in human myeloma. , 2012, Blood.
[38] G. Baysoy,et al. Outcome of enzyme replacement therapy in Turkish patients with Gaucher disease: does late intervention affect the response? , 2011, The Turkish journal of pediatrics.
[39] S. Plon,et al. Insights into the pathogenesis and treatment of cancer from inborn errors of metabolism. , 2011, American journal of human genetics.
[40] Y. Baruch,et al. Gaucher's disease type I: a disease masked by the presence of abnormal laboratory tests common to primary liver disease. , 2010, European journal of gastroenterology & hepatology.
[41] M. Machaczka,et al. Treatment of multiple myeloma in patients with Gaucher disease , 2009, American journal of hematology.
[42] G. Rennert,et al. The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients , 2009, American journal of hematology.
[43] J. Charrow,et al. Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1 , 2009, Genetics in Medicine.
[44] J. M. Aerts,et al. ‘Non-neuronopathic’ Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature , 2008, Journal of Inherited Metabolic Disease.
[45] C. Hollak,et al. Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature , 2008, Annals of Hematology.
[46] N. Khurana,et al. Pseudo-Gaucher cells in Hb E disease and thalassemia intermedia , 2007, Hematology.
[47] J. Yee,et al. Consequences of diagnostic delays in type 1 Gaucher disease: The need for greater awareness among Hematologists–Oncologists and an opportunity for early diagnosis and intervention , 2007, American journal of hematology.
[48] C. Hollak,et al. Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease , 2007, British journal of haematology.
[49] H. Ida,et al. Pseudo-Gaucher Cell Proliferation Associated with Myelodysplastic Syndrome , 2007, International journal of hematology.
[50] J. Charrow,et al. Gaucher disease and cancer incidence: a study from the Gaucher Registry. , 2005, Blood.
[51] Fernando A. Arosa,et al. Evidence for a link between sphingolipid metabolism and expression of CD1d and MHC‐class II: monocytes from Gaucher disease patients as a model , 2005, British journal of haematology.
[52] L. Boon,et al. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. , 2004, American journal of clinical pathology.
[53] A. Lebeau,et al. Generalized crystal-storing histiocytosis associated with monoclonal gammopathy: molecular analysis of a disorder with rapid clinical course and review of the literature. , 2002, Blood.
[54] R. Proia,et al. Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage. , 2002, The Journal of clinical investigation.
[55] N. Radin. The Development of Aggressive Cancer: A Possible Role for Sphingolipids , 2002, Cancer investigation.
[56] K. Possinger,et al. Coincidence of Gaucher's disease due to a 1226G/1448C mutation and of an immunoglobulin G lambda multiple myeloma with Bence-Jones proteinuria , 2000, Annals of Hematology.
[57] A. J. Stewart,et al. Pseudo-Gaucher cells in myelodysplasia. , 1999, Journal of clinical pathology.
[58] R. Hartsock,et al. Pseudo-Gaucher cells in the bone marrow of a patient with Hodgkin's disease. , 1987, American journal of clinical pathology.
[59] M. Machaczka,et al. Atypical cytomorphology of Gaucher cells is frequently seen in bone marrow smears from untreated patients with Gaucher disease type 1. , 2015, Folia histochemica et cytobiologica.
[60] M. Pandey,et al. Immunological cells and functions in Gaucher disease. , 2013, Critical reviews in oncogenesis.
[61] D. Hughes,et al. Gaucher disease and myeloma. , 2013, Critical reviews in oncogenesis.
[62] T. Taddei,et al. Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism. , 2013, Critical reviews in oncogenesis.
[63] W. Cheung,et al. Type I Gaucher disease following chemotherapy for light chain multiple myeloma. , 2007, Internal medicine.
[64] D. Häussinger,et al. Increased incidence of cancer in adult Gaucher disease in Western Europe. , 2006, Blood cells, molecules & diseases.
[65] S. Rajkumar,et al. MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management. , 2005, Hematology. American Society of Hematology. Education Program.
[66] A. Brautbar,et al. Effect of enzyme replacement therapy on gammopathies in Gaucher disease. , 2004, Blood cells, molecules & diseases.
[67] G. Rossi,et al. Pseudo-Gaucher plasma cells in the bone marrow of a patient with monoclonal gammopathy of undetermined significance. , 1997, Haematologica.
[68] N. Rushton,et al. Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10. , 1997, QJM : monthly journal of the Association of Physicians.
[69] A. Saven,et al. Misuse of marrow examination in the diagnosis of Gaucher disease. , 1990, Blood.
[70] P. Anderson,et al. Phenotypic and Genetic Variation , 1980 .